fda warning letters glp-1 september 2025 news FDA takes aim at telehealth companies for promoting unofficial weight loss drug dupes

Today, the FDA established a “green list” import alert to help stop potentially dangerous GLP-1 active pharmaceutical ingredients from unverified foreign sources from entering the U.S. market. The agency will continue to

20.64

★★★★☆4.8 (126)

FDA Warning Letter Breakdown: Sterility Failures, Subpotent GLP-1 Drugs, and a Compounding Pharmacy Operating Without Control

20.23

★★★★★4.9 (98)

Thinking about buying GLP-1 and other products labeled “for research purposes” or “not for human consumption”? Think again. These products have not been reviewed by FDA for safety, effectiveness or quality and

21.68

★★★★★5.0 (157)

Thinking about buying GLP-1 and other products labeled “for research purposes” or “not for human consumption”? Think again. These products have not been reviewed by FDA for safety, effectiveness or

25.24

★★★★★4.7 (84)

The FDA has issued a warning to Novo Nordisk over its alleged failure to report adverse side effects, including death, in patients who took its GLP-1 medications, popularly known as Ozempic and

22.13

★★★★★4.9 (203)

The FDA sent a warning letter to the maker of Ozempic and Wegovy over unreported potential GLP-1 side effects. Here's what to know

23.79

★★★★★5.0 (176)

FDA Issues 30 Warning Letters to Telehealth Firms Over Misleading Compounded GLP-1 Marketing

26.32

★★★★★4.8 (132)